This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vorinostat and Palliative Radiotherapy (PRAVO)

This study has been completed.
Information provided by:
Oslo University Hospital Identifier:
First received: April 2, 2007
Last updated: July 21, 2011
Last verified: July 2011
April 2, 2007
July 21, 2011
February 2007
Not Provided
DLT [ Time Frame: continously ]
Not Provided
Complete list of historical versions of study NCT00455351 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Vorinostat and Palliative Radiotherapy
Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Phase I study. Side-effects when combined with standard palliative radiotherapy.
Not Provided
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Pelvic Cancer
  • Radiotherapy
Drug: Vorinostat
Increasing dosing, phase I
Experimental: A I
Study drug
Intervention: Drug: Vorinostat

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2009
Not Provided

Inclusion Criteria:

  • Pelvic malignancy
  • Palliative radiation treatment planed
  • ECOG <3
  • Age>18 years

Exclusion Criteria:

  • Previous pelvic radiotherapy
  • Uncontrolled diarrhea
  • Insulin-dependent diabetes mellitus
  • BMI<18.5
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
EudraCTnumber 2006-003631-76
Not Provided
Not Provided
Svein Dueland (PI), Rikshospitalet-Radiumhospitalet HF
Oslo University Hospital
Not Provided
Study Director: Sigbjørn Smeland, MD,PhD Norwegian Radium Hospital
Oslo University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP